Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: GastroIntestinal Bleeding. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States, Brazil, China, Germany, India +3
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding: A Prospective, International Multicenter, Observational Study
Overview
Acute gastrointestinal bleeding is potentially lethal in liver cirrhosis. Accurate assessment of prognosis is critical in a timely fashion. A novel model, CAGIB score, has been developed based on our Chinese multicenter retrospective study. Now, a prospective, international multicenter, observational study will be performed to further compare the performance of CAGIB versus Child-Pugh and MELD scores for evaluating the in-hospital mortality of patients with liver cirrhosis and acute gastrointestinal bleeding.
Primary outcome measures
- Mortality [Time frame: An average of 1-6 weeks, from admission to discharge]
Secondary outcome measures (1)
- Failure to control bleeding within 5 days [Time frame: 5 days]
Eligibility criteria
Inclusion criteria
- Patients with liver cirrhosis;
- Patients with acute gastrointestinal bleeding presenting with hematemesis, melena, and/or hematochezia;
- Adults (age≥18 years old).
Exclusion criteria
- Components of Child-Pugh, MELD, and CAGIB scores are not available;
- In-hospital outcomes are not evaluable.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
China · 16 centers
- Beijing Youan Hospital, Capital Medical University — Beijing
- The Seventh Medical Center of Chinese PLA General Hospital — Beijing
- First Affiliated Hospital of Fujian Medical University — Fuzhou
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan
- First Affiliated Hospital of Nanchang University — Nanchang
- The Six People's Hospital of Dalian — Dalian
- Air Force Hospital of Northern Theater Command — Shenyang
- General Hospital of Northern Theater Command — Shenyang
- … and 8 more centers
United States · 1 center
- The Wright Center for Graduate Medical Education, 501 S. Washington Avenue — Scranton
Brazil · 1 center
- São Paulo State University (UNESP), Botucatu Medical School — São Paulo
Germany · 1 center
- Charité University Medical Center — Berlin
India · 1 center
- Ernakulam Medical Center — Kochi
Italy · 1 center
- Azienda di Rilievo Nazionale ad Alta Specializzazione Civico-Di Cristina-Benfratelli — Palermo
Mexico · 1 center
- National Autonomous University of Mexico — Mexico City
Turkey (Türkiye) · 1 center
- Bezmialem Vakif University — Istanbul
Publications
- Bai Z, Li B, Lin S, Liu B, Li Y, Zhu Q, Wu Y, Yang Y, Tang S, Meng F, Chen Y, Yuan S, Shao L, Qi X. Development and Validation of CAGIB Score for Evaluating the Prognosis of Cirrhosis with Acute Gastrointestinal Bleeding: A Retrospective Multicenter Study. Adv Ther. 2019 Nov;36(11):3211-3220. doi: 10.1007/s12325-019-01083-5. Epub 2019 Sep 11. PMID 31512140
- Marcondes MB, Moreno CF, Suzuki CMP, Rodrigues MAG, Moreira A, Qi X, Romeiro FG. Impact of Cirrhosis Etiology and Intensive Care Accessibility on Upper Gastrointestinal Bleeding: A Prospective Observational Study. Can J Gastroenterol Hepatol. 2026;2026(1):e1409025. doi: 10.1155/cjgh/1409025. PMID 42216795
- Zhang S, Sun M, Yuan S, Lin S, Romeiro FG, He Y, Zhu Q, Ma D, Li Y, Philips CA, Liu X, Mendez-Sanchez N, Shao L, Wu Y, Basaranoglu M, Pinyopornpanish K, Chen Y, Mancuso A, Yang L, Tacke F, Li B, Liu L, Ji F, Qi X. Identifying Low-Risk Patients with Cirrhosis and Acute Gastrointestinal Bleeding That May Not Require Urgent Endoscopy. Adv Ther. 2026 Jan;43(1):288-303. doi: 10.1007/s12325-025-03395-1. PMID 41273618
- Bai Z, Lin S, Sun M, Yuan S, Marcondes MB, Ma D, Zhu Q, Li Y, He Y, Philips CA, Liu X, Pinyopornpanish K, Shao L, Mendez-Sanchez N, Basaranoglu M, Wu Y, Chen Y, Yang L, Mancuso A, Tacke F, Li B, Liu L, Ji F, Qi X. Machine learning based CAGIB score predicts in-hospital mortality of cirrhotic patients with acute gastrointestinal bleeding. NPJ Digit Med. 2025 Jul 31;8(1):489. doi: 10.1038/s41746-025 PMID 40745090
Identifiers
NCT: NCT04662918 · V-CAGIB 1.0